Department of Medical Laboratory Science, Gimhae College, Gimhae, Korea.
Brain Korea 21 Plus Program, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea.
Ann Lab Med. 2021 Jul 1;41(4):409-413. doi: 10.3343/alm.2021.41.4.409.
Phospholipase C beta 2 (PLC-β2) regulates various essential functions in cell signaling, differentiation, growth, and mobility. We investigated the clinical implications of PLC-β2 protein expression in newly diagnosed normal karyotype acute myeloid leukemia (NK-AML). The PLC-β2 expression status in bone marrow tissues obtained from 101 patients with NK-AML was determined using semiquantitative immunohistochemistry (IHC). IHC results were compared with those for known prognostic markers. Using a cutoff score for positivity of 7.0, the PLC-β2 overexpression group showed superior overall survival (OS) (72.6% vs. 26.5%; =0.016) and low hazard ratio (HR) (0.453; =0.019) compared with the PLC-β2 low-expression group. The PLC-β2 overexpression group showed no significant gain in event-free survival (50.6% vs. 43.0%, =0.465) and HR (0.735; =0.464). Among the known prognostic markers, only positivity was associated with a significantly low OS and high HR. In conclusion, PLC-β2 overexpression was associated with favorable OS in NK-AML patients. Our results suggest that PLC-β2 expression assessment using IHC allows prognosis prediction in NK-AML.
磷酸脂酶 Cβ2（PLC-β2）调节细胞信号、分化、生长和迁移等各种基本功能。我们研究了 PLC-β2 蛋白在新诊断的正常核型急性髓系白血病（NK-AML）中的表达的临床意义。使用半定量免疫组织化学（IHC）检测 101 例 NK-AML 患者骨髓组织中的 PLC-β2 表达状态。将 IHC 结果与已知的预后标志物进行比较。使用阳性截取值为 7.0，PLC-β2 过表达组的总生存（OS）（72.6% vs. 26.5%；=0.016）和低风险比（HR）（0.453；=0.019）优于 PLC-β2 低表达组。PLC-β2 过表达组在无事件生存（EFS）（50.6% vs. 43.0%，=0.465）和 HR（0.735；=0.464）方面没有显著提高。在已知的预后标志物中，只有 FLT3-ITD 阳性与显著降低的 OS 和高 HR 相关。总之，PLC-β2 过表达与 NK-AML 患者的有利 OS 相关。我们的结果表明，使用 IHC 评估 PLC-β2 表达可预测 NK-AML 的预后。
